AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Rhea-AI Summary

AEON Biopharma (NYSE: AEON) reported inducement grants totaling 392,158 restricted stock units (RSUs) to newly hired non-executive employees, approved under the company’s 2025 Inducement Incentive Plan.

The grants have a grant date of December 11, 2025, vesting commencement dates in December 2025, and vest 25% annually over four years. Awards are subject to the Inducement Plan and individual RSU agreement terms and were issued as inducement material under Section 711 of the NYSE American Company Guide.

Key Figures

RSU grants 392,158 RSUs Inducement awards to newly hired non-executive employees under 2025 plan

Vesting period 4 years RSUs vest 25% on each annual anniversary

Grant date December 11, 2025 Grant date for inducement RSU awards

Current price $1.08 Price before this RSU news, up 6.93% over 24 hours

52-week range $0.375 – $49.1112 Stock trading 97.8% below 52-week high and 188% above low

Market Reality Check

$1.11 Last Close

Volume Volume 289,395 is 1.84x the 20-day average of 156,975 ahead of this RSU announcement. high

Technical Price at $1.08 is trading above the 200-day MA of $0.75 after a long decline from the $49.11 52-week high.

Peers on Argus 1 Up

Biotech peers showed mixed moves: CSCI -8.11%, DWTX +5.74%, RNAZ +4.07%, while AEON gained 6.93%, suggesting today’s strength is company-specific rather than a broad sector trade.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Debt exchange deal	Positive	+5.1%	Exchange of Daewoong convertible notes into equity, new note, and warrants.
Nov 20	PIPE and FDA timing	Positive	-12.8%	First PIPE closing and rescheduled FDA Type 2a meeting to Jan 21, 2026.
Nov 14	Earnings and pipeline	Positive	-3.8%	Q3 results, positive ABP-450 biosimilarity data, PIPE financing, and debt-cut plans.

Pattern Detected

Recent news often involved balance-sheet restructuring and financings; the stock rose on the latest debt-exchange announcement but declined on earlier positive financing and data updates, showing mixed alignment between fundamentals and price moves.

Recent Company History

Over the last few months, AEON has focused on strengthening its balance sheet and funding ABP-450 biosimilar development. On Nov 14, 2025, it reported Q3 results with positive biosimilarity data, a $6 million PIPE, and plans to cut debt by >90%, yet shares fell 3.77%. A Nov 20, 2025 PIPE closing and FDA meeting update saw a 12.79% drop. By Dec 15, 2025, a Daewoong exchange agreement driving >90% debt reduction led to a 5.1% gain. Today’s RSU inducement grants fit into this broader equity-centric capital strategy.

Market Pulse Summary

This announcement details 392,158 RSUs granted as inducement awards to new non-executive employees under AEON’s 2025 Inducement Incentive Plan, vesting over four years. It follows months of balance-sheet restructuring and financings to support ABP-450 biosimilar development. Investors may track how total equity-based compensation evolves relative to the company’s small $13.94M market cap and prior exchanges, along with progress on regulatory milestones for ABP-450.

Key Terms

restricted stock units financial

"grants in December totaling 392,158 restricted stock units (RSUs) of the Company’s"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"392,158 restricted stock units (RSUs) of the Company’s common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

inducement incentive plan financial

"approved by the Company’s Board of Directors under the Company’s 2025 Inducement Incentive Plan"

An inducement incentive plan is a program that gives stock, options, or other pay tied to company shares to new hires as a lure to join the business. Think of it like a signing bonus paid in future ownership instead of cash. Investors watch these plans because they dilute existing shareholders, change management incentives, and signal how aggressively a company must recruit talent to grow, which can affect future value.

vesting commencement date financial

"with a grant date of December 11, 2025 and vesting commencement dates in December 2025"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

AI-generated analysis. Not financial advice.

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today reported the grants in December totaling 392,158 restricted stock units (RSUs) of the Company’s common stock to newly hired non-executive employees of the Company. The awards were approved by the Company’s Board of Directors under the Company’s 2025 Inducement Incentive Plan, with a grant date of December 11, 2025 and vesting commencement dates in December 2025.

The RSUs vest over four years, 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The awards are being granted as inducement material to new employees entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.

About the U.S. Biosimilar Pathway

The U.S. Food and Drug Administration (“FDA”) regulates biosimilars under the Public Health Service Act’s 351(k) pathway, which require developers to demonstrate that a proposed product is highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Analytical similarity is the scientific foundation of this process, representing the most critical and data-intensive phase of development. Once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on confirming whether any residual uncertainty requires limited clinical evaluation.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. The Company’s lead asset is ABP-450 for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Contacts

Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com

Source: AEON Biopharma

FAQ

How many RSUs did AEON (NYSE: AEON) grant in December 2025?

AEON granted 392,158 restricted stock units (RSUs) in December 2025.

What is the vesting schedule for the AEON RSU grants dated December 11, 2025?

The RSUs vest over four years with 25% vesting each annual anniversary of the vesting commencement date.

Were the AEON RSU awards issued under a specific plan or NYSE rule?

Yes, the awards were approved under AEON’s 2025 Inducement Incentive Plan and issued as inducement material under Section 711 of the NYSE American Company Guide.

Who received the inducement RSU grants from AEON on December 11, 2025?

The grants were awarded to newly hired non-executive employees entering employment with AEON.

Do the December 2025 AEON RSU awards include special terms or conditions?

Yes, the awards are subject to the terms and conditions of the Inducement Plan and the applicable RSU agreement covering each grant.